Conditions

Younger patients with type 1 diabetes may require extra monitoring to avoid adverse glycemic events

Combined analysis of eGFR and albuminuria over 2 years has been shown to predict T2DM patients’ risk for major macrovascular outcomes.

Final results from a phase 3 study preceded FDA approval of oral semaglutide.

A secondary analysis of the LEADER trial to investigate the safety of liraglutide in patients with type 2 diabetes. 

Both patients and HCPs should be aware of early signs of kidney issues.

People with metabolically healthy obesity may not remain free of metabolic diseases in the long term.

Patients with diabetes are two times more likely to present with symptoms of depression; how does this affect diabetes outcomes?

A recent study demonstrates the efficacy of a new, once daily oral option for patients with type 2 diabetes already on metformin. 

Is the Oral Glucose Challenge Test necessary in low-risk pregnant patients?

Does giving children with type 1 diabetes insulin before each meal help them lower their HbA1c?